Study on Recombinant Zoster Vaccine (RZV)
Background and Objective
Researchers aimed to find out if the RZV vaccine could reduce the severity of herpes zoster cases in adults.
Methods
The study analyzed data from three clinical trials to compare the impact of RZV on the quality of life for vaccinated and unvaccinated individuals who had breakthrough cases of herpes zoster.
Results
- The difference in quality-adjusted life-year (QALY) losses between the two groups was estimated to be 0.007 QALYs.
- RZV was found to reduce disease severity, with vaccinated individuals experiencing 35.5% to 48.6% lower QALY loss compared to unvaccinated individuals.
Conclusions
The study concluded that RZV is effective in reducing the severity of herpes zoster cases, which is important for health economics studies and cost-effectiveness analyses.
For full clinical trial report, click here.
